A
Alessandro Colasanti
Researcher at King's College London
Publications - 65
Citations - 3172
Alessandro Colasanti is an academic researcher from King's College London. The author has contributed to research in topics: Medicine & Translocator protein. The author has an hindex of 26, co-authored 51 publications receiving 2681 citations. Previous affiliations of Alessandro Colasanti include Hammersmith Hospital & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Robin L. Carhart-Harris,David Erritzoe,Timothy Williams,James M. Stone,Laurence J. Reed,Alessandro Colasanti,Robin J. Tyacke,Robert Leech,Andrea Malizia,Kevin Murphy,Peter Hobden,John Evans,Amanda Feilding,Richard G. Wise,David J. Nutt +14 more
TL;DR: Psilocybin caused a significant decrease in the positive coupling between the mPFC and PCC, which strongly imply that the subjective effects of psychedelic drugs are caused by decreased activity and connectivity in the brain's key connector hubs, enabling a state of unconstrained cognition.
Journal ArticleDOI
Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.
Massimo C. Mauri,L.S. Volonteri,Alessandro Colasanti,Alessio Fiorentini,Ilaria Francesca De Gaspari,Silvio R. Bareggi +5 more
TL;DR: This review of the literature concerning the relationships between plasma concentrations of SGAs and clinical responses is divided by dividing the studies on the basis of the length of their observation periods by indicating a relationship between clinical outcomes and plasma concentrations.
Journal ArticleDOI
Clinical pharmacology of atypical antipsychotics: an update.
Massimo Carlo Mauri,Silvia Paletta,M. Maffini,Alessandro Colasanti,Filippo Dragogna,C. Di Pace,Alfredo Carlo Altamura +6 more
TL;DR: Four new second-generation antipsychotics are available: iloperidone, asenapine, lurasidone and in the next future cariprazine, and these new agents are advisable for the lower propensity to give weight gain and metabolic abnormalities in comparison with older second- Generation antipsychotic drugs such as olanzapine or clozapine.
Journal ArticleDOI
Within-subject comparison of [(11)C]-(+)-PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans.
Paul Shotbolt,Andri C. Tziortzi,Andri C. Tziortzi,Graham E. Searle,Alessandro Colasanti,Jasper van der Aart,Sergio Abanades,Christophe Plisson,Sam R Miller,Mickael Huiban,John D. Beaver,Roger N. Gunn,Roger N. Gunn,Marc Laruelle,Marc Laruelle,Eugenii A. Rabiner +15 more
TL;DR: [11C]- ( + )-PHNO is superior to [11C]raclopride for studying acute fluctuations in synaptic dopamine in the human striatum using a within-subjects, counterbalanced, open-label design.
Journal ArticleDOI
Substance abuse in first-episode schizophrenic patients: a retrospective study
TL;DR: The findings seem to indicate that substance abuse in the early course of illness determines an earlier onset of schizophrenia and increases severity of some psychotic symptoms like "hallucination" and "unusual content of thought".